Treatment Landscape in R/R DLBCL Novel Targets and Strategies. Wyndham H. Wilson, M.D., Ph.D. Senior Investigator
|
|
- Gerard Wood
- 5 years ago
- Views:
Transcription
1 Treatment Landscape in R/R DLBCL Novel Targets and Strategies Wyndham H. Wilson, M.D., Ph.D. Senior Investigator
2 Gene-expression profiling of DLBCL subtypes Roschewski, M. et al. (2013) Nat. Rev. Clin. Oncol.
3 Key signaling pathways in GCB DLBCL Targeting PI3K Roschewski, M. et al. (2013) Nat. Rev. Clin. Oncol.
4 Genetic aberrations activating PI3K pathway in hematologic malignancies Deletion PTEN 10q23 locus: 10% GCB Inactivation PTEN: 55% GCB and 14% ABC DLBCL Mutation distribution suggests relevant in GCB > ABC (Testoni et al. Ann Oncol 2015)
5 Copanlisip: PI3 Kinase pan-class I inhibitor 40 Relapsed/refractory DLBCL ORR 25%; 50% CR Subset by COO GCB ORR 13.6% ABC ORR 37.5% ORR not associated with mutations BCL2 (54%); TP53 (41%); BCL6 (30%); MYC (22%); CD79A/B (25%); MYD88 (19%); TNFAIP3 (17%); CARD1 (13%)1 Lenz et al, ASCO Proceedings, 2017 Better response rate in ABC Interaction of PI3K with BCR signaling likely important
6 Key signaling pathways in GCB DLBCL Targeting mtor and AKT Nelfinovir Everolimus Roschewski, M. et al. (2013) Nat. Rev. Clin. Oncol.
7 Everolimus in R/R Aggressive Lymphoma Disease type N ORR (95 CI) CR PR Total (20 41) 3 20 DLBCL (17 45) 0 14 MCL (13 57) 2 4 FL-III 8 38 (9 76) 1 2 Other ! Witzig et al. Leukemia (2011) 25,
8 GCB ABC 56% BCL-2 Translocations in GCB DLBCL Malignant transformation BCL2 translocation mir amplification Apoptosis mtor activation BCL2 amplification NF-kappa B Malignant transformation Apoptosis PTEN deletion ING1 deletion MDM2 gain or amplification P53 mutation MYC translocation Genomic instability Interleukin-6 and interleukin-10 19q gain or amplification Trisomy 3 INK4A-ARF deletion STAT3 IRF4 SPIB FOXP1 Senescence Essential regulatory network Genomic instability AID MYC amplification Aberrant switch translocations Germinal center B-cell Plasmablast Plasma cell
9 GCB ABC BCL-2 Amplification In ABC DLBCL Malignant transformation Malignant transformation BCL2 translocation mir amplification Apoptosis mtor activation BCL2 amplification NF-kappa B Apoptosis PTEN deletion ING1 deletion MDM2 gain or amplification P53 mutation MYC translocation Genomic instability Interleukin-6 and interleukin-10 19q gain or amplification Trisomy 3 INK4A-ARF deletion STAT3 IRF4 SPIB FOXP1 Senescence Essential regulatory network Genomic instability AID MYC amplification Aberrant switch translocations Germinal center B-cell Plasmablast Plasma cell
10 BCL-2-Rearrangement versus Expression
11 GCB MYC translocation in GCB ABC Malignant transformation Malignant transformation BCL2 translocation mir amplification Apoptosis mtor activation BCL2 amplification NF-kappa B Apoptosis 10% PTEN deletion ING1 deletion MDM2 gain or amplification P53 mutation MYC translocation Genomic instability Interleukin-6 and interleukin-10 19q gain or amplification Trisomy 3 INK4A-ARF deletion STAT3 IRF4 SPIB FOXP1 Senescence Essential regulatory network Genomic instability AID MYC amplification Aberrant switch translocations Germinal center B-cell Plasmablast Plasma cell
12 GCB ABC MYC amplification In ABC Malignant transformation Malignant transformation BCL2 translocation mir amplification Apoptosis mtor activation BCL2 amplification NF-kappa B Apoptosis PTEN deletion ING1 deletion MDM2 gain or amplification P53 mutation MYC translocation Genomic instability Interleukin-6 and interleukin-10 19q gain or amplification Trisomy 3 INK4A-ARF deletion STAT3 IRF4 SPIB FOXP1 Senescence Essential regulatory network Genomic instability AID MYC amplification Aberrant switch translocations Germinal center B-cell Plasmablast Plasma cell
13
14 Key signaling pathways in GCB DLBCL Targeting BCL-2 Venetoclax (ABT-199) Roschewski, M. et al. (2013) Nat. Rev. Clin. Oncol.
15 Davids et al JCO 2016 Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
16 Davids et al JCO 2016 Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
17 Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Unimpressive response rate in DLBCL DE does not appear to increase ORR Davids et al JCO 2016
18 Venetoclax in DLBCL How do you select patients? Role of combination treatment? ABT-199, Ibrutinib and Lenalidomide: drug vs drug interactions Synergy (deltabliss SumNeg) Thomas et al NCI data
19 NF-kB Target Genes Are Highly Expressed in Targeting NFKB in ABC DLBCL Activated B Cell-like Diffuse Large B Cell Lymphoma NF-kB target gene Lymphoma biopsy samples Staudt et al NCI data
20 BCR and MYD88 Pathways IRAK4(inhibitors( Ibru%nib( Ruxoli%nib( SB15108( Idelalisib( Ibru%nib( Enzastaurin( Sotrastaurin( MALT(inhibitors( Everolimus( Temsirolimus( Bortezomib( Lenalidomide( IRF4(
21
22 Figure 1 Ibrutinib in ABC DLBCL a Evaluable tumor (% change from baseline in SPD) ABC GCB b % Response (CR + PR) (14/38) CR PR (0/4) ABC * (1/20) PR GCB c 1.0 Median PFS (months) d 1.0 Median OS (months) Probability of survival ABC GCB Probability of survival ABC GCB ** *** Progression-free survival (months) Overall survival (months) At risk: ABC: At risk: ABC: GCB: GCB: Wilson et al Nat Med 2015
23 Ibrutinib in ABC DLBCL Hyperaddiction % response (CR + PR) % response (CR + PR) 50 (10/25) (4/12) 40 (1/3) 30 (4/5) (0/7) 0 0 Mutant WT CD79B: Mutant Mutant WT MYD88 TIR MYD88: WT Mutant Mutant domain All other: 12/35 10/32 14/30 P value: vs. other Live cells (% DMSO) * % response (CR + PR) (0/3) 0 Mutant (8/24) WT CARD11 coiled-coil domain % response (CR + PR) (0/5) 0 Inactive (8/21) WT TNFAIP3 Ibrutinib (nm) Cell line: HBL1 DLBCL subtype: ABC MYD88 mutation: L265P BCR mutation: CD79B TMD8 ABC L265P CD79B Ly10 ABC L265P CD79A Hyperaddiction HLY1 ABC S219C WT SUDHL2 ABC S222R WT BJAB GCB WT WT Ly1 GCB WT WT Ly8 GCB WT WT Wilson et al Nat Med 2015
24 Phoenix Trial Targeting BTK in Untreated ABC DLBCL! Phase III double blind randomized study R-CHOP ± Ibrutinib! International Registration trial 800 patients (Janssen sponsor)! Study Completed Accrual 2015! Tumors analyzed for molecular subtype and NGS (Staudt et al)
25 Primary CNS Lymphoma Mutations in MYD88 and CD79 Mutation Summary Any: 76% CD79B: 53% MYD88: 56% Both: 37% Suggest hyper addiction to BCR signaling
26 Primary CNS Lymphoma 282 Untreated Patients MSKCC Abrey et al. JCO 2006, 24:5711
27 Phase I Study of Ibrutinib and TEDDi-R Objectives " Ibrutinib response rate " Ibrutinib safe tolerated dose with DA- TEDDI-R " DA-TEDDi-R response and duration " Tumor mutations in CD79 and MYD88
28 DA-TEDDi-R Development TMD8 Cell Line Ibrutinib-Cytotoxic Drug Killing B 0 DNA damage Anti-folate C 7 DNA damage Anti-folate -1 6 DBSumNeg value (Ibrutinib synergy) DBSumPos value (Ibrutinib antagonism) Doxorubicin Etoposide Cytarabine Methotrexate Raltitrexed Pralatrexate DNA damage Anti-folate 1 0 Doxorubicin Etoposide Cytarabine Methotrexate Raltitrexed Pralatrexate DNA damage Anti-folate
29 Dose Adjusted-TEDDI-R No MTX Temozolomide"100"mg/m 2 /day"po"days"2"to"5" Etoposide"50"mg/m 2 /day"iv"days"2"to"5"" Doxil"50"mg/m 2 "IV"day"2""" Dexamethasone"10"mg/m 2 "BID"PO"days"1"to"5" Ibru6nib"(560%TBD"mg)"PO"days"%14"to"5"" Rituximab"375"mg/m 2 "IV"on"days"1"and"2"" Filgras6m"300"μg"SQ"on"days"6+"un6l"ANC>5,000"(past"nadir)"""" """Cytarabine"70"mg""IT"or"ICV"on"days"1"and"5"of"cycles"2"to"6" Ibrutinib window """"""Filgras6m"300"μg"SQ"on"days"6+" un6l"anc>5,000"(past"nadir)" D%14" d%1" d"1" d"2" d"3" d"4" d"5" d"6" d"7" d"8" d"9" d"10" Repeat"cycle"q21"days"x"6" Dose%Adjustment:"Etoposide"and"Temozolomide""increase"20%"if"ANC"nadir">"500""
30 Patient Characteristics Characteristics N= 18 Age (median) 66 years (49-87) Age > 60 years 67% Male gender 61% Untreated 28% (5/18) Refractory to standard treatment 77% (10/13) Relapsed 23% (3/13) Prior Rx (median) Prior Autologous Transplant 2 (1-6) 4 (31%) IELSG risk >=2 83% Wilson et al. Cancer Cell 2017
31 Pharmacokinetics of Ibrutinib 840 mg and PCI (active metabolite) CSF times above ibrutinib IC50: 24 hours AUC csf/plasma corrected for protein Binding: 29%
32 Ibrutinib Response in 14-day Window A. 250 Ibrutinib monotherapy (n=18) Disease reduction from baseline * Relapsed/ refractory Previously untreated -100 *
33 TEDDi-R Response D. Prior treatment status Refractory Untreated Refractory Untreated Refractory Relapsed Untreated Relapsed Refractory Untreated Untreated Refractory Refractory Refractory Refractory Refractory Refractory Refractory Months on study Pt. # CR 12 PR 13 SD PD 16 Death NE
34 DA-TEDDi-R PFS R/R PCNSL Median follow-up of 31.2 mos Median PFS not yet reached 2-year PFS: 54.5% (95% CI: %)
35 Kiyasu et al. Blood 2015; 126:2193 PD-L-1 Expression in 262 DLBCL Samples
36 PD-L-1 Expression Associated with Lower Survival Kiyasu et al. Blood 2015; 126:2193
37 PD-1 Blockade with Nivolumab in R/R PCNSL PCNSL Patients: N= 5 Refractory N=1; Relapsed N=4 CR N=4; PR N=1 PFS 13+; 14; 14+; 17; 17+ Nayak et al. Blood 2017; 129:3071
38 Novel Targets in R/R DLBCL Targeting PI3K/AKT-mTOR in GCB and ABC Targeting Bcl-2 in ABC and GCB Single agent activity poor-synergy with BTK targets Role in double hit versus double expressor unknown Ibrutinib targets BCR in ABC High activity in PCNSL PD-1 inhibition in PCNSL and extranodal ABC
Aggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV
Aggressive lymphomas ASH 2015 Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV CHOP 1992 2002 R-CHOP For DLBCL High dose chemo With PBSCT Aggressive lymphomas 1.DLBCL 2.Primary Mediastinal Lymphoma 3.CNS
More informationGenomics in diffuse large B cell lymphoma (DLBCL) not as useful as we thought. OR IS IT?
Genomics in diffuse large B cell lymphoma (DLBCL) not as useful as we thought. OR IS IT? Matt McKinney MD Instructor in Medicine, Division of Hematologic Malignancies, Department of Medicine Duke University
More informationPI3K Inhibitors. Anas Younes, M.D. chief, Lymphoma Service Memorial Sloan Kettering Cancer Center
PI3K Inhibitors Anas Younes, M.D. chief, Lymphoma Service Memorial Sloan Kettering Cancer Center Targeting PI3K/AKT/mTOR Pathway PI 3-kinase Α, β, γ, δ Idelalisib Duvelisib Copanlisib TGR-122 Buparlisib
More informationDiffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA
Diffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA Disclosures Consulting advice: Hospira, Bayer, Juno Therapeutics, Teva, Oncotracker, Gilead
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationPI3K Inhibitors in Follicular Lymphoma. Anas Younes, M.D. chief, Lymphoma Service Memorial Sloan Kettering Cancer Center
PI3K Inhibitors in Follicular Lymphoma Anas Younes, M.D. chief, Lymphoma Service Memorial Sloan Kettering Cancer Center PI3K Pathway mutations do correlate with pathway activation in lymphoma How to measure
More informationTreatment Nodal Marginal Zone Lymphoma
Workshop : Indolent lymphomas Treatment Nodal Marginal Zone Lymphoma Catherine Thieblemont Hôpital Saint-Louis, Paris - France Bologna 16th, 2017 Ø No standardized treatment Ø Similarly treated as FL Treatment
More informationOSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD
OSCO/OU ASH-SABC Review Lymphoma Update Mohamad Cherry, MD Outline Diffuse Large B Cell Lymphoma Double Hit Lymphoma Follicular and Indolent B Cell Lymphomas Mantle Cell Lymphoma T Cell Lymphoma Hodgkin
More informationHave we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES!
Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES! Christopher Flowers, MD, MSc Associate Professor Director, Lymphoma Program Department of Hematology and Oncology Emory School of Medicine
More informationAggressive B-cell lymphomas and gene expression profiling towards individualized therapy?
Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy? Andreas Rosenwald Institute of Pathology, University of Würzburg, Germany Barcelona, June 18, 2010 NEW WHO CLASSIFICATION
More informationCNS Lymphoma. Las Vegas-- March 10-12, 2016
CNS Lymphoma Las Vegas-- March 10-12, 2016 Frequency 3% of primary cerebral tumors 1% of NHLs Recent developments and controversies in PCNSL Hottinger et al Current Opinion in Oncology Vol 27 No. 6 November
More informationLymphoma Update 2018
Lymphoma Update 2018 Sonali M. Smith, MD Elwood V. Jensen Professor of Medicine Section of Hematology/Oncology Director, Lymphoma Program The University of Chicago April 18, 2018 Disclosure Information
More informationAggressive B and T cell lymphomas: Treatment paradigms in 2018
Aggressive B and T cell lymphomas: Treatment paradigms in 2018 John P. Leonard M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Associate
More informationPivotal Genetic Pathways Influencing Treatment in Lymphoma. Philip J. Bierman, M.D. April 24, 2015
Pivotal Genetic Pathways Influencing Treatment in Lymphoma Philip J. Bierman, M.D. April 24, 2015 Personalized Treatment in Lymphoma What is Personalized Therapy? Customized therapy Individualized therapy
More informationTargeting Bruton s Tyrosine Kinase (BTK)
Targeting Bruton s Tyrosine Kinase (BTK) Lapo Alinari, MD, PhD 4 th International Conference, Translational Research in Oncology Forli, November 9-11/2016 The Ohio State University Comprehensive Cancer
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationMANTLE CELL LYMPHOMA MTOR-INHIBITION
MANTLE CELL LYMPHOMA MTOR-INHIBITION Rome, 23. March 2017 Prof. Dr. med. Georg Heß III. Med. Klinik Universitäres Centrum für Tumorerkrankungen Universitätsmedizin der Johannes Gutenberg-Universität Mainz
More informationDurable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive doublehit
Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive doublehit DLBCL treated with lenalidomide monotherapy Running head: Durable remission with lenalidomide in CNS relapse
More informationNuclear Export Inhibition: Selinexor in Non-Hodgkin s Lymphoma. 10 May 2016, Bologna Italy
Nuclear Export Inhibition: Selinexor in Non-Hodgkin s Lymphoma 10 May 2016, Bologna Italy Selinexor: First-in-Class, Oral Selective Inhibitor of Nuclear Export (SINE) Novel, small molecule selective inhibitor
More informationVenetoclax in MCL. Prof. Le Gouill Nantes Medical University, France
Venetoclax in MCL Prof. Le Gouill Nantes Medical University, France Evasion of Apoptosis, or Cell Death, is 1. Resisting Cell Death 2. Sustained angiogenesis for growth and survival (primarily solid tumors)
More informationMantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents
Mantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Friday March 16, 2018: 11:15-11:30
More informationESMO DOUBLE-HIT LYMPHOMAS
ESMO DOUBLE-HIT LYMPHOMAS Professor Dr. med. Georg Lenz Director Department of Hematology and Oncology Universitätsklinikum Münster, Germany OVERVIEW Definition of double-hit lymphomas Introduction in
More informationDouble hit lymphoma Clinical perspectives
Double hit lymphoma Clinical perspectives Peter Johnson Some definitions, for clarity Double-hit lymphoma (5% of DLBL) Rearranged MYC (8q24) by FISH Plus either rearranged BCL2 (18q21) or BCL6 (3q27) Double-expression
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationLymphoid Malignancies Think Tank Therapeutic Opportunities in Lymphomas
Lymphoid Malignancies Think Tank Therapeutic Opportunities in Lymphomas Wyndham H. Wilson, MD, PhD Bethesda, Maryland Distribution of Lymphoma Subtypes % of Total Cases Diffuse La rge B-ce ll Follicular
More informationManagement of high-risk diffuse large B cell lymphoma: case presentation
Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January
More informationAggressive B-cell Lymphomas
Neoplastic Hematopathology Update 2018 Aggressive B-cell Lymphomas Raju K. Pillai City of Hope National Medical Center I do not have any disclosures Disclosures Outline New entities and changes in WHO
More information2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용
2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas
More informationNovel treatment options for Waldenstrom Macroglobulinemia
Novel treatment options for Waldenstrom Macroglobulinemia Irene Ghobrial, MD Associate Professor of Medicine Harvard Medical School Dana Farber Cancer Institute Boston, MA Ghobrial et al, Lancet Oncol
More informationPathology of aggressive lymphomas
Institute of Pathology Pathology of aggressive lymphomas Leticia Quintanilla-Martinez Changes in the new 2016 WHO Aggressive B-cell lymphoid neoplasms Major changes that impact how cases should be evaludated
More informationTreating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma
Treating Frail Adults With Common Malignancies: Best Evidence to Personalize Therapy Treating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma Raul Cordoba, MD, PhD Lymphoma Unit
More informationMantle cell lymphoma An update on management
Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag
More informationAggressive B cell Lymphomas
Aggressive B cell Lymphomas I have nothing to disclose. Disclosures Raju K. Pillai City of Hope National Medical Center Outline WHO 2016 Classification Large B cell Lymphomas New entities and changes in
More informationAdvances in haematological malignancies focus on lymphoid disease
Advances in haematological malignancies focus on lymphoid disease Dr Kylie Mason MBBS PhD FRACP FRCPA Haematologist Bone marrow Transplant Physician Clinician Scientist The Royal Melbourne Hospital The
More informationLow grade Non-Hodgkin Lymphoma: New Therapies & Updates
Low grade Non-Hodgkin Lymphoma: New Therapies & Updates Craig A. Portell MD Assistant Professor of Medicine ivision of Hematology/Oncology University of Virginia Friday, April 28, 2017 Disclosures I have
More informationDiffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe founded in 1985 Comparison of Two Consecutive Study Generations of the GLSG Overall Survival Follicular Lymphomas Questions for the Next Steps of
More informationBuilding a Leading Oncology Franchise
ASDAQ: MEIP Building a Leading Oncology Franchise 17th Annual eedham Healthcare Conference March 27, 2018 Forward-Looking Statements This presentation contains, and our officers and representatives may
More informationInternational Conference on Malignant Lymphoma (ICML) June 14-17, 2017
International Conference on Malignant Lymphoma (ICML) June 14-17, 2017 INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR: CLINICAL ACTIVITY AND FAVORABLE SAFETY IN PATIENTS
More informationRelapsed/Refractory Diffuse Large B-Cell Lymphoma John Kuruvilla, MD Princess Margaret Cancer Centre University of Toronto
Relapsed/Refractory Diffuse Large B-Cell Lymphoma John Kuruvilla, MD Princess Margaret Cancer Centre University of Toronto Disclosures Research Support Employee Leukemia and Lymphoma Society US, Rasch
More informationRecent advances in the genetics & biology of lymphoma
Recent advances in the genetics & biology of lymphoma Chris Bacon Northern Institute for Cancer Research Newcastle University & Newcastle Upon Tyne Hospitals NHS Foundation Trust Lymphoma Rate per 100,000
More informationState of the Art Treatment for Relapsed Mantle Cell Lymphoma
Winship Cancer Institute of Emory University State of the Art Treatment for Relapsed Mantle Cell Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor, BMT Program Emory University- Winship Cancer Institute
More informationBTK Inhibitors and BCL2 Antagonists
BTK Inhibitors and BCL2 Antagonists Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia and Indolent Lymphoma, Peter MacCallum Cancer
More informationPathology of aggressive lymphomas
Institute of Pathology Pathology of aggressive lymphomas Leticia Quintanilla-Martinez Changes in the new 2016 WHO Aggressive B-cell lymphoid neoplasms Major changes that impact how cases should be evaludated
More informationMantle Cell Lymphoma. A schizophrenic disease
23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More information2012 by American Society of Hematology
2012 by American Society of Hematology Common Types of HIV-Associated Lymphomas DLBCL includes primary CNS lymphoma (PCNSL) Burkitt Lymphoma HIV-positive patients have a 60-200 fold increased incidence
More informationJanssen Hematologic Malignancy Portfolio
Janssen Hematologic Malignancy Portfolio Recorded Webcast: Update for Analysts and Investors January 216 Oncology 1 Safe Harbor Statement This webcast contains "forward-looking statements" as defined in
More informationLymphoma update: turning biology into cures. Peter Johnson
Lymphoma update: turning biology into cures Peter Johnson Selected highlights of recent research 1. Using FDG-PET to modify treatment and avoid long term toxicity in Hodgkin lymphoma 2. Understanding how
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationACCME/Disclosures. DLBCL, NOS from the clinician perspective. Diffuse large B cell lymphoma
, NOS from the clinician perspective John P. Leonard, M.D. Weill Cornell Medicine New York Presbyterian Hospital ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the
More informationLymphoma- Med A-new drugs and treatments
Lymphoma- Med A-new drugs and treatments Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Disclosures: Roche, Gilead Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Outline Lymphoma- what is
More informationWe Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT
We Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT Danielle M. Brander, MD Duke University Division of Hematologic Malignancies & Cell Therapy CLL & Indolent
More informationFollicular Lymphoma 2016:
Follicular Lymphoma 2016: Evolving Management Strategies Randeep Sangha, MD Medical Oncology, Cross Cancer Institute Associate Professor, University of Alberta Edmonton, AB Disclosures I have no actual
More information*Jagiellonian University, Kraków, Poland
Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin s Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study Wojciech Jurczak, *
More informationNHL DLBCL PDX Models. Evaluate novel therapies and combination regimens in PDX models fully characterized for DLBCL related genes
PDX Models Evaluate novel therapies and combination regimens in PDX models fully characterized for related genes Accelerate your targeted agent and combination therapy drug discovery programs with CrownBio
More informationINTRODUCTION TO THE MOLECULAR BIOLOGY OF LYMPHOMA
INTRODUCTION TO THE MOLECULAR BIOLOGY OF LYMPHOMA January 29, 2016 Urban Novak, MD Medical Oncology Inselspital Bern CANCERS HARBOR GENETIC LESIONS... Melanoma: ~33 000 changes in the DNA!!! Acquired throughh
More informationHigh-Grade B-cell Lymphoma Double Hit or Double Expressing
High-Grade B-cell Lymphoma Double Hit or Double Expressing Professeur Alexandra Traverse-Glehen Hematopathology Hospices Civils de Lyon Université Lyon 1 France MYC-R confer inferior pronostic DOUBLE/TRIPLE
More informationSecond Generation BTK Inhibitors Acalabrutinib (ACP-196) and Zanubrutinib (BGB-3111)
Second Generation BTK Inhibitors Acalabrutinib (ACP-196) and Zanubrutinib (BGB-3111) Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia
More informationNovita da EHA 2016 Copenhagen Linfomi
Firenze, 16th September 2016 Marco Ladetto MD, Az Osp Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy EU Novita da EHA 2016 Copenhagen Linfomi THREE QUESTIONS TO ADDRESS: 1. Is ASCT still the
More informationAggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017
Aggressive NHL and Hodgkin Lymphoma Dr. Carolyn Faught November 10, 2017 What does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks
More informationTailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?
EVOLVING STRATEGIES IN AGGRESSIVE B-CELL LYMPHOMA Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently? Andrew Davies Cancer Research UK Centre, Cancer Sciences
More informationDiffuse Large B-cell Lymphoma: Is Cell of Origin Necessary for Treatment Selection?
Diffuse Large B-cell Lymphoma: Is Cell of Origin Necessary for Treatment Selection? Andrew D. Zelenetz, MD, PhD Memorial Sloan Kettering Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients
More informationWaldenström s Macroglobulinemia: Treatment Approach
Waldenström s Macroglobulinemia: Treatment Approach Steve Treon MD, PhD Bing Center for Waldenstrom s Macroglobulinemia Dana Farber Cancer Institute Harvard Medical School Primary Therapy of WM with Rituximab
More informationVENETOCLAX (ABT 199) Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth
VENETOCLAX (ABT 199) Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth ABT-199 Venetoclax ABT-199 is a selective, potent, orally
More informationState of the art: CAR-T cell therapy in lymphoma
State of the art: CAR-T cell therapy in lymphoma 14 th annual California Cancer Consortium conference Tanya Siddiqi, MD City of Hope Medical Center 8/11/18 Financial disclosures Consultant for Juno therapeutics
More informationChronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD
Chronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang-Mai University Outline
More informationPOST ICML Indolent lymphomas relapse treatment
POST ICML Indolent lymphomas relapse treatment Georg Hess University Medical School Johannes Gutenberg-University Mainz, Germany Treatment of relapsed indolent lymphoma 2 General categories of second line
More informationAggressive B-cell Lymphomas Updated WHO classification Elias Campo
Aggressive B-cell Lymphomas Updated WHO classification Elias Campo Hospital Clinic, University of Barcelona Diffuse Large B-cell Lymphoma A Heterogeneous Category Subtypes with differing: Histology and
More informationConflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center
What Is Personalized Medicine For Patients With Lymphoma? Conflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center DISCLOSURE I have no potential
More informationPrevalent lymphomas in Africa
Prevalent lymphomas in Africa Dr Zainab Mohamed Clinical Oncologist GSH/UCT Groote Schuur Hospital Disclaimer I declare that I have no conflict of interest Groote Schuur Hospital Denis Burkitt 1911-1993
More informationResponse and resistance to BRAF inhibitors in melanoma
Response and resistance to BRAF inhibitors in melanoma Keith T. Flaherty, M.D. Massachusetts General Hospital Cancer Center Disclosures Roche/Genentech: consultant GlaxoSmithKline: consultant BRAF mutations
More informationAggressive B cell Lymphomas
Aggressive B cell Lymphomas Raju K. Pillai City of Hope National Medical Center I have no disclosures Outline What is new in the WHO 2016 classification Insights from genomic studies Double Hit Lymphoma
More informationTARGETING EZH2 WITH TAZEMETOSTAT IN FOLLICULAR LYMPHOMA
TARGETING EZH2 WITH TAZEMETOSTAT IN FOLLICULAR LYMPHOMA VINCENT RIBRAG Chairman hematological multidisciplinary committee Ditep (chief molecular therapeutics in hematological early drug development) Bologna
More informationClinical Research in Medical Oncology
Clinical Research in Medical Oncology Adam M. Petrich, MD Northwestern University June 2, 2015 Objectives Why oncology? Why lymphoma? Why clinical research? Discuss various phases and objectives of clinical
More informationImmune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust
Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint
More informationAGRESSIVE LYMPHOMAS - FUTURE. Dr Stéphane Doucet CHUM
AGRESSIVE LYMPHOMAS - FUTURE Dr Stéphane Doucet CHUM What are clinical trials? Clinical trials are carefully planned research studies where the most-promising discoveries and results from laboratory studies
More informationBcl-2 inhibition in NHL. Jonathan W. Friedberg M.D., M.M.Sc.
Bcl-2 inhibition in NHL Jonathan W. Friedberg M.D., M.M.Sc. BCL-2, BH3 and apoptosis: Rational therapeutic targets in NHL Antiapoptotic proteins, prevent activation of Bax and Bak, thus inhibiting apoptosis.
More informationClinical Trial News on the Treatment of Waldenstrom s Macroglobulinemia
Clinical Trial News on the Treatment of Waldenstrom s Macroglobulinemia Edward Libby M.D. Associate Professor, University of Washington Department of Medicine, Division of Medical Oncology Fred Hutchinson
More informationMantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients
Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France
More informationNew agents for recurrent FL
Lymphoma and Myeloma 2015 Meeting New agents for recurrent FL Sven de Vos, MD, PhD Director, UCLA Lymphoma Program Los Angeles, CA Indolent Lymphoma Percent Survival Year 60 mos 120 mos 1944-54 29.3 17.2
More informationNon-Hodgkin s and Hodgkin lymphoma: using disease characteristics as a guide to treatment selection. Arnold Freedman, M.D.
2017 Master Class for Oncologists Non-Hodgkin s and Hodgkin lymphoma: using disease characteristics as a guide to treatment selection Arnold Freedman, M.D. 2018 Master Class Course Disclosure Disclosure
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationConstan'ne S Tam Victorian Comprehensive Cancer Center Melbourne, Australia
Constan'ne S Tam Victorian Comprehensive Cancer Center Melbourne, Australia BGB-3111: Kinase Selec.vity Rela.ve to Ibru.nib Equipotent against BTK compared to ibru.nib Higher selec.vity vs EGFR, ITK, JAK3,
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationFuture Strategies For Refractory Myeloma. Marc S. Raab
Future Strategies For Refractory Myeloma Marc S. Raab Multiple Myeloma Clonal proliferation of malignant plasma cells. excess bone marrow plasma cells monoclonal protein osteolytic bone lesions renal disease
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationTranslocations and clonality detection in lymphoproliferative disorders by capturebased Next-generation sequencing
Translocations and clonality detection in lymphoproliferative disorders by capturebased Next-generation sequencing Dörte Wren MSc MPhil on behalf of the EuroClonality-NGS consortium Molecular Diagnostics
More informationHodgkin Lymphoma New Combo-Steps
New Drugs In Hematology Hodgkin Lymphoma New Combo-Steps Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 2:55-3:10 p.m Combinations with Immune Checkpoint
More informationChanging the landscape of treatment in Peripheral T-cell Lymphoma
Changing the landscape of treatment in Peripheral T-cell Lymphoma Luis Fayad Associate Professor MD Anderson Cancer Center Department of Lymphoma and Myeloma 1 6 What is peripheral 2008 WHO CLASSIFICATION
More informationSimposio COSA È CAMBIATO NELL APPROCCIO TERAPEUTICO DEI LINFOMI NON HODGKIN DEL PAZIENTE ANZIANO?
58 Congresso Nazionale Società Italiana di Gerontologia e Geriatria Torino 27-30 novembre 2013 Simposio COSA È CAMBIATO NELL APPROCCIO TERAPEUTICO DEI LINFOMI NON HODGKIN DEL PAZIENTE ANZIANO? C è un ruolo
More informationCAR-T CELLS: NEW HOPE FOR CANCER PATIENTS
CAR-T CELLS: NEW HOPE FOR CANCER PATIENTS Natasha Kekre, MD, MPH, FRCPC Hematologist, Blood and Marrow Transplant Program, TOH Associate Scientist, Ottawa Hospital Research Institute Assistant Professor
More informationPost-ESMO Berne
Post-ESMO Berne 23.10.2015 Lymphoma Update Panagiotis Samaras Department of Oncology Hemato-Oncology Center University Hospital Zurich Diffuse Large B-Cell Lymphoma (DLBCL) PCNSL Hodgkin s Lymphoma Mantle
More informationExpert Perspective on ASH 2014: Lymphoma
Expert Perspective on ASH 2014: Lymphoma Myron S. Czuczman, MD Abstract The 2014 Annual Meeting and Exposition of the American Society of Hematology included many updates of previously presented studies,
More informationTarGeting B-Cell Diseases
TarGeting B-Cell Diseases Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements
More informationMechanism for targeting CDK4, BTK and PI3K in Mantle Cell Lymphoma. Selina Chen-Kiang, Ph.D. Weill Cornell Medicine
Mechanism for targeting CDK4, BTK and PI3K in Mantle Cell Lymphoma Selina Chen-Kiang, Ph.D. Weill Cornell Medicine Goal To develop mechanism-based therapy in mantle cell lymphoma Effective, tolerable,
More informationSHIFTING TREATMENT PARADIGMS IN NON-HODGKIN LYMPHOMAS
SHIFTING TREATMENT PARADIGMS IN NON-HODGKIN LYMPHOMAS This symposium took place on 22 nd June 2017, as part of the 22 nd Congress of the European Hematology Association (EHA) in Madrid, Spain Chairperson
More information